The aim of the Youth Depression Alleviation-Combined Treatment (YoDA-C) study is to determine whether antidepressant medication should be started as a first-line treatment for youth depression delivered concurrently with psychotherapy. Doubts about the use of medication have been raised by meta-analyses in which the efficacy and safety of antidepressants in young people have been questioned, and subsequent treatment guidelines for youth depression have provided only qualified support.
Methods:
YoDA-C is a double-blind, randomised controlled trial funded by the Australian government’s National Health and Medical Research Council.
Participants between the ages of 15 and 25 years with moderate to severe major depressive disorder will be randomised to receive either (1) cognitive behavioural therapy (CBT) and fluoxetine or (2) CBT and placebo. The treatment duration will be 12 weeks, and follow-up will be conducted at 26 weeks.
The primary outcome measure is change in the Montgomery-Asberg Depression Rating Scale (MADRS) after 12 weeks of treatment. The MADRS will be administered at baseline and at weeks 4, 8, 12 and 26.
Secondary outcome measures will address additional clinical outcomes, functioning, quality of life and safety.Trial registration: Australian and New Zealand Clinical Trials Registry ID: ACTRN12612001281886 (registered on 11 December 2012)
Author: Christopher G DaveyAndrew M ChanenSue M CottonSarah E HetrickMelissa J KerrMichael BerkOlivia M DeanKally YuenMark PhelanAswin RatheeshMiriam R SchäferG Paul AmmingerAlexandra G ParkerDanijela PiskulicSusy HarriganAndrew J MackinnonBen J Harrison
Published on: 2014-11-04
Tweet
News Provider: 7thSpace Interactive / EUPB Press Office
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
There are no comments available. Be the first to write a comment.